Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosed B-cell chronic lymphocytic leukemia (CLL) defined by the National Cancer Institute (NCI) Working Group criteria~* Meets 1 of the following criteria:~  * Binet stage C disease~ * Binet stage B disease AND ≥ 1 of the following signs or symptoms\*:~    * B symptoms (night sweats, weight loss ≥ 10% within the previous 6 months, fevers \> 38°C or 100.4°F for ≥ 2 weeks without evidence of infection), or constitutional symptoms (fatigue)~   * Continuous progression (doubling of peripheral lymphocyte count within the past 6 months and absolute lymphocyte count \> 50 G/I)~   * Evidence of progressive marrow failure as manifested by the development/worsening of anemia and/or thrombocytopenia~   * Massive, progressive or painful splenomegaly or hypersplenism~   * Massive lymph nodes or lymph node clusters (\> 10 cm in longest diameter), danger of organ complications through large lymphoma (e.g., vascular compression or tracheal narrowing), or progressive lymphadenopathy~   * Occurrence of symptomatic hyperviscosity problems at leukocyte counts \> 200 G/I (symptomatic leukostasis) NOTE: \* Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease is not sufficient for eligibility~* No Binet stage A disease~* No transformation to an aggressive B-cell malignancy (e.g., diffuse large cell lymphoma, Richter's syndrome, or prolymphocytic leukemia)~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Cumulative Illness Rating Scale (CIRS) score \> 6~* Life expectancy \> 6 months~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* Alkaline phosphatase and transaminases ≤ 2 times ULN~* Creatinine clearance ≥ 70 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 2 months after study treatment~* No known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the study drugs~* No cerebral dysfunction that precludes chemotherapy~* No active bacterial, viral, or fungal infection~* No clinically significant autoimmune cytopenia or Coombs-positive hemolytic anemia~* No other active malignancy requiring concurrent treatment except basal cell carcinoma or tumors treated curatively by surgery~* No medical or psychological condition that would preclude study therapy~* No concurrent disease that requires prolonged (\> 1 month) therapy involving glucocorticoids~PRIOR CONCURRENT THERAPY:~* No previous treatment of CLL by chemotherapy, radiotherapy, or immunotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fludarabine+Cyclophosphamide+Rituximab (FCR) (Type: EXPERIMENTAL): None
- Fludarabine+Cyclophosphamide (FC) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).